- Open Access
“Mouse Clone Model” for evaluating the immunogenicity and tumorigenicity of pluripotent stem cells
Stem Cell Research & Therapy volume 6, Article number: 255 (2015)
To investigate the immune-rejection and tumor-formation potentials of induced pluripotent stem cells and other stem cells, we devised a model—designated the “Mouse Clone Model”—which combined the theory of somatic animal cloning, tetraploid complementation, and induced pluripotent stem cells to demonstrate the applicability of stem cells for transplantation therapy.
In 2011, Zhao et al.  reported that, compared with embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) showed more immune rejection and overexpression of immunogenicity-related genes. This report shed shadows on the great promise of iPSCs as the renewable sources of autologous cells for regenerative medicine. Because of the different origins and treatment of ESCs and iPSCs [2–4], it is reasonable that there are some differences between them, even though iPSCs can eventually give rise to viable mice by tetraploid complementation [5, 6] and iPSC mice can make further mice . These data demonstrate that iPSCs could have the same pluripotency as ESCs. At present, iPSCs can be generated with several different protocols, including retroviral infection , lentiviral transduction , nonviral minicircle vector transfection , and so forth. It is true that a heterogeneic situation will always be found in iPSCs. Polo et al.  reported that iPSCs derived from different cell types, such as mouse fibroblasts, hematopoietic cells, and myogenic cells, exhibited distinct transcriptional and epigenetic patterns. Furthermore, the cellular origin influences the in vitro differentiation potentials of iPSCs. But continuous passaging of iPSCs largely attenuates these differences. These data indicate that the heterogeneity of iPSCs might be decreased by further reprogramming with more passaging . Great achievements have so far been made in the application of iPSC transplantation. For example, the successful corrections of sickle cell anemia, Fanconi anemia, and tyrosinemia [11–13] via the transplantation of iPSC-derived differentiated cell types into diseased mouse models.
The shortcoming of this research is to use the same strain of C57BL/6 (B6) mice as recipients to test the immune rejection of the iPSCs, derived from mice which are within the same strain but are not the same individual mice, between the donors of iPSCs and the recipients . For example, C57BL/6 mice are an inbred strain and are nearly identical to each other in genotype due to long inbreeding. Although transplantations between inbred mice have been conventionally used as a model to test immune acceptance and are considered autologous transplantation, and in some sense they are in theory equivalent to autologous human tissue/cell transplantations, this is not completely true. Here, it is worthy of note that inbred mice are nearly identical in genotype, but they are not exactly the same. Furthermore, even though it is well known that inbred mice can fully accept the same inbred strain mouse organs, including skin grafts, and therefore are a rigorous model to assess immune tolerance, this might not be the same in the case of stem cell transplantation therapy, such as iPSC and ESC transplantations. It is well known that immune rejection exists not only species specifically, but also individual specifically, including within the same strain, due to alloimmunity .
To evaluate the applicability of iPSCs for autologous transplantation, we devised a novel animal model by combining the theory of animal cloning , the protocol of tetraploid complementation , and the induction of iPSCs [3, 4, 7] to establish a large number of cloned mice derived from a single inner cell mass (ICM) of mouse blastocyst (Fig. 1). The reasons for using ESCs as the first step include, first of all, that we can compare the similarity and difference between ESCs and iPSCs of the same origin, because they are genetically from the same mouse blastocyst. In addition, by using ESCs as the starting point, we can produce both ESC mice and iPSC mice, so we can compare them to determine whether they are exactly the same or have some differences. Theoretically, these cloned mice are exactly identical to each other. Therefore, truly autologous stem cell transplantations can be performed between them. Moreover, because the starting point of the cloned mice is the ESCs, the transplantation characteristics among ESCs, iPSCs, and tissue-specific stem cells can be analyzed with this model. Adopting this clone of mice as a unique source, iPSC lines can be induced and established. At the same time, other stem cells of different tissues can also be isolated. As a result, the iPSCs and tissue-specific stem cells, together with their progenies of different differentiated stages, can be tested by transplanting them into the mice of the same clone to achieve truly autologous transplantation to mimic human patient-specific iPSCs for the patients (Fig. 1). In addition, during the reprogramming of iPSCs, some genetically different cell lines with different pluripotency can be generated by different protocols and other unknown reasons [1, 3, 5–7]; therefore, this model can also help to answer which lines are better for therapeutic applications with less immune rejection. Furthermore, the availability of plenty of the same-origin clone of mice can further allow the investigators to examine the therapeutic advantages of various kinds of tissue-specific stem cells with different differentiated stages. The discovery that mice can be serially recloned for up to 25 generations with consistent cloning efficiency and without evident genomic errors indicated that mice possibly can be recloned limitlessly by the somatic nuclear transfer method . Thus, in theory, mice can also possibly be limitlessly recloned by tetraploid complementation strategy with iPSCs. Hence, iPSCs can be isolated and induced limitlessly from these iPSC mice.
Although autoimmune diseases exist, and in some cases the transplantation tolerance observed in mouse models cannot be validated in large animal models and human due to different species, this strategy will at least theoretically provide a clone of truly identical mice for stem cell therapy investigation. Using this method, a clone of immortal mice can be established eventually, and they will benefit the stem cell therapy research greatly in a mouse–mouse pattern. In conclusion, this model—the “Mouse Clone Model”—can provide an unprecedented strategy to vigorously assess the safety of mouse ESCs, iPSCs, and various kinds of tissue-specific stem cells in “themselves”. Using this model in mouse stem cell transplantation, we can, in theory, avoid using immunodeficient mice and inbred mice to study stem cell transplantation because of their disadvantages (Table 1). For human stem cell therapy, because we cannot directly test iPSCs and other stem cells in the human body, some of the major concerns such as immune rejection and tumor formation after transplantation cannot be determined vigorously. With this model, we can at least investigate whether or not the in vitro culture procedure, induction, and differentiation might cause problems for immune rejection and tumor formation in mice. If we can prove experimentally that the in vitro culture, induction, and differentiation procedure cannot induce immune rejection and cancer formation using this mouse model, then we can gain more confidence that the patient-derived iPSCs might be used for transplantation. Certainly, there are many differences for stem cell transplantation between mice and human, but it is worth trying. This model will therefore lay important foundations for personalized patient-specific tissue stem cells and iPSCs for transplant therapy.
Another concern about stem cell transplantation therapy is tumor formation. The discovery of cancer stem cells (CSCs) demonstrated that, in the hierarchy of the cancer cell population, there is a subset of stem-like tumor cells that have the ability to self-renew and differentiate into the diverse tumor cells [18–21]. There are good reasons to believe that during the in vitro culture of stem cells, and particularly the in vitro induction with viral integrations of iPSCs, stem cells are exposed to risks for some mutations and epigenetic changes [22–24]. Thus, after transplantation into recipients, the stem cells, in some cases, can result in various tumors [25–28]. Different immune-deficient mice are commonly used as recipients, to facilitate the integration of transplanted stem cells. On the other hand, due to their deficiency of immunity, some stem cells can accumulate to form tumors when they undergo clonal evolution [25, 26]. Using the “Mouse Clone Model” for mouse stem cell transplantation, theoretically—because the recipients and stem cells and their derivatives are “selves” and have “normal” immunity—the risks of forming tumors would be decreased radically. This “Mouse Clone Model” could therefore not only reduce the immune rejection radically, but also decrease the risks of tumor formation significantly. The advantages and disadvantages of different mouse models are briefly presented in Table 1; for more details, refer to .
Ideally, the applicable iPSCs for transplantation therapy should have full pluripotency, such as supporting full iPSC mice. This is the gold standard for full pluripotency for mouse ESCs and iPSCs. In addition, the iPSCs and their differentiated stem cells should not form tumors. Compared with currently used animal models for intraspecies stem cell transplantation, the “Mouse Clone Model” is much more advantageous for the following investigations: to investigate the immune rejection of established stem cell lines, including iPSCs and various tissue-specific stem cells, and to select suitable stem cell lines and cloned mice based on the immune rejection data; to investigate the tumor formation of iPSCs and other stem cell lines and to select suitable stem cells and cloned mice that possess low or absent tumorigenicity based on the tumor formation assay ; to investigate, after the selection of applicable stem cells and mice, the appropriate stages of different stem cells for their transplantation; and to genetically decipher the mechanisms of immune rejection and tumor formation more precisely. Because the stem cells and the mouse clone are biologically “selves”, this model will provide much stronger and direct evidence for stem cell therapy, and further give instructions for patient-specific iPSC-based therapy clinically. We suggest that stem cell researchers all over the world should investigate the applicability of iPSCs and tissue-specific stem cells for therapeutic applications taking advantage of this model.
Cancer stem cell
Embryonic stem cell
Inner cell mass
Induced pluripotent stem cell
Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212–5.
Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1981;78:7634–8.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.
Jincho Y, Araki R, Hoki Y, Tamura C, Nakamura M, Ando S, et al. Generation of genome integration-free induced pluripotent stem cells from fibroblasts of C57BL/6 mice without c-Myc transduction. J Biol Chem. 2010;285:26384–9.
Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. iPS cells produce viable mice through tetraploid complementation. Nature. 2009;461:86–90.
Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell. 2009;5:135–8.
Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. Adult mice generated from induced pluripotent stem cells. Nature. 2009;461:91–4.
Wernig M, Lengner CJ, Hanna J, Lodato MA, Steine E, Foreman R, et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol. 2008;26:916–24.
Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods. 2010;7:197–9.
Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol. 2010;28:848–55.
Hanna J, Wernig M, Markoulaki S, Chiao-Wang Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920–3.
Raya A, Rodríguez-Pizà I, Guenechea G, Vassena R, Navarro S, Barrero MJ, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53–9.
Wu G, Liu N, Rittelmeyer I, Sharma AD, Sgodda M, Zaehres H, et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol. 2011;9:e1001099.
Seetharam A, Tiriveedhi V, Mohanakumar T. Alloimmunity and autoimmunity in chronic rejection. Curr Opin Organ Transplant. 2010;15:531–6.
Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810–3.
Tam PPL, Rossant J. Mouse embryonic chimeras: tools for studying mammalian development. Development. 2003;22:6155–63.
Wakayama S, Kohda T, Obokata H, Tokoro M, Li C, Terashita Y, et al. Successful serial recloning in the mouse over multiple generations. Cell Stem Cell. 2013;12:293–7.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.
Barabe F, Kenedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316:600–4.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature. 2004;432:396–401.
Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25:207–15.
Maitra A, Arking DE, Shivapurkarv N, Ikeda M, Stastny V, Kassauei K, et al. Genomic alterations in cultural human embryonic stem cells. Nat Genet. 2005;37:1099–103.
Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout 3rd WM, Biniszkiewicz D, et al. Epigenetic instability in ES cells and cloned mice. Science. 2001;293:95–7.
Shih CC, Forman SJ, Chu P, Slovak M. Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev. 2007;16:893–902.
Fujikawa T, Oh SH, Pi L, Hatch HM, Shupe T, Petersen BE. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol. 2005;166:1781–91.
Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009;27:1050–6.
Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–7.
Belizário JE. Immunodeficient mouse models: an overview. Open Immunol J. 2009;2:79–85.
The authors declare that they have no competing interests.
Both authors read and approved the final manuscript.
About this article
Cite this article
Zhang, G., Zhang, Y. “Mouse Clone Model” for evaluating the immunogenicity and tumorigenicity of pluripotent stem cells. Stem Cell Res Ther 6, 255 (2015) doi:10.1186/s13287-015-0262-3
- Stem Cell
- Pluripotent Stem Cell
- Stem Cell Therapy
- Fanconi Anemia